Sight Sciences (NASDAQ:SGHT - Free Report) had its target price decreased by Stifel Nicolaus from $6.00 to $5.00 in a research report report published on Thursday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.
Several other research firms also recently weighed in on SGHT. Citigroup decreased their target price on Sight Sciences from $5.80 to $4.60 and set a "neutral" rating for the company in a research report on Wednesday, December 11th. Morgan Stanley reduced their target price on shares of Sight Sciences from $7.00 to $5.00 and set an "equal weight" rating on the stock in a research report on Monday, November 11th. Needham & Company LLC reiterated a "hold" rating on shares of Sight Sciences in a report on Tuesday, January 14th. Lake Street Capital reduced their price objective on Sight Sciences from $5.00 to $3.00 and set a "hold" rating on the stock in a report on Wednesday, January 15th. Finally, Piper Sandler reiterated a "neutral" rating and issued a $5.50 target price (down from $6.00) on shares of Sight Sciences in a report on Friday, November 8th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $4.68.
Get Our Latest Report on SGHT
Sight Sciences Price Performance
Shares of NASDAQ:SGHT traded down $0.10 on Thursday, reaching $2.67. The company's stock had a trading volume of 96,537 shares, compared to its average volume of 225,070. The company has a 50-day simple moving average of $3.33 and a 200 day simple moving average of $4.92. Sight Sciences has a 52-week low of $2.66 and a 52-week high of $8.45. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18. The company has a market cap of $135.53 million, a P/E ratio of -2.62 and a beta of 2.52.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. The business had revenue of $20.16 million for the quarter, compared to analysts' expectations of $20.41 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. As a group, equities research analysts anticipate that Sight Sciences will post -1 EPS for the current fiscal year.
Insider Buying and Selling
In related news, CEO Paul Badawi sold 12,236 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $3.60, for a total transaction of $44,049.60. Following the completion of the sale, the chief executive officer now owns 5,713,197 shares of the company's stock, valued at $20,567,509.20. This represents a 0.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last three months, insiders purchased 15,000 shares of company stock worth $58,232 and sold 63,014 shares worth $197,295. 28.90% of the stock is currently owned by company insiders.
Institutional Trading of Sight Sciences
Several hedge funds and other institutional investors have recently made changes to their positions in SGHT. KCK LTD. purchased a new position in shares of Sight Sciences in the fourth quarter worth $15,925,000. Millrace Asset Group Inc. purchased a new position in Sight Sciences in the 3rd quarter worth $874,000. State Street Corp lifted its position in Sight Sciences by 17.4% during the 3rd quarter. State Street Corp now owns 646,776 shares of the company's stock worth $4,075,000 after acquiring an additional 95,843 shares during the period. Jacobs Levy Equity Management Inc. grew its stake in Sight Sciences by 46.3% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 207,893 shares of the company's stock valued at $1,310,000 after purchasing an additional 65,767 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Sight Sciences by 335.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 69,660 shares of the company's stock worth $439,000 after buying an additional 53,658 shares during the period. Hedge funds and other institutional investors own 55.51% of the company's stock.
Sight Sciences Company Profile
(
Get Free Report)
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Featured Stories
Before you consider Sight Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.
While Sight Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
